FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eunice Kwak

Research Profile

Chemicals & Drugs

Disorders

Physiology

Concepts & Ideas

Treatment Outcome

Procedures

Antineoplastic Combined Chemotherapy Protocols

Co-author Network

Publications

TOP 3
Ioannis T Konstantinidis; Eunice L Kwak; Gregory Y Lauwers; Keith D Lillemoe; David P Ryan; Jennifer A Wargo; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Cristina R Ferrone
Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Brian M Wolpin; Andrew X Zhu; Thomas Abrams; Jill N Allen; Pankaj Bhargava; Lawrence S Blaszkowsky; Jennifer A Chan; Meaghan Elliot; Peter C Enzinger; Wolfram Goessling; Eunice L Kwak; Nadine J McCleary; Jeffrey A Meyerhardt; Kimmie Ng; Eileen Regan; Kaori Sato; Deborah Schrag; Jeffrey G Supko; Charles S Fuchs
Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
Michael S Lee; Harvey J Mamon; Jeffrey A Meyerhardt; David W Rattner; David P Ryan; Raphael Bueno; Noah C Choi; Dean M Donahue; Panagiotis M Fidias; Charles S Fuchs; Theodore S Hong; Michael T Jaklitsch; Eunice L Kwak; Michael Lanuti; Peter C Enzinger
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eunice Kwak (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ioannis T Konstantinidis; Eunice L Kwak; Gregory Y Lauwers; Keith D Lillemoe; David P Ryan; Jennifer A Wargo; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Cristina R Ferrone
Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Annals of surgery 2013;257(4):731-6.
2013: Brian M Wolpin; Andrew X Zhu; Thomas Abrams; Jill N Allen; Pankaj Bhargava; Lawrence S Blaszkowsky; Jennifer A Chan; Meaghan Elliot; Peter C Enzinger; Wolfram Goessling; Eunice L Kwak; Nadine J McCleary; Jeffrey A Meyerhardt; Kimmie Ng; Eileen Regan; Kaori Sato; Deborah Schrag; Jeffrey G Supko; Charles S Fuchs
Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
The oncologist 2013;18(4):377-8.
2013: Michael S Lee; Harvey J Mamon; Jeffrey A Meyerhardt; David W Rattner; David P Ryan; Raphael Bueno; Noah C Choi; Dean M Donahue; Panagiotis M Fidias; Charles S Fuchs; Theodore S Hong; Michael T Jaklitsch; Eunice L Kwak; Michael Lanuti; Peter C Enzinger
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.
The oncologist 2013;18(3):281-7.
2013: Theodore S Hong; Jennifer Y Wo; Eunice L Kwak
Targeted therapies with chemoradiation in esophageal cancer: development and future directions.
Seminars in radiation oncology 2013;23(1):31-7.
2012: D Ross Camidge; Jeffrey W Clark; Daniel B Costa; Jeffrey A Engelman; Panagiotis Fidias; Stephen B Fox; Leena Gandhi; A John Iafrate; Pasi A Janne; Dong-Wan Kim; Eunice L Kwak; Patricia M LoRusso; Sai-Hong I Ou; Gregory J Riely; Katherine Ruffner; Ravi Salgia; Geoffrey I Shapiro; Benjamin Solomon; Patricia Stephenson; Yiyun Tang; Marileila Varella-Garcia; Keith Wilner; Yung-Jue Bang; Alice T Shaw
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
The lancet oncology 2012;13(10):1011-9.
2012: Jason E Faris; Aram F Hezel; Thomas A Abrams; Jamie Arnott; Lawrence S Blaszkowsky; Jeffrey W Clark; Peter C Enzinger; Kimmie Ng; David P Ryan; Brian M Wolpin; Hui Zheng; Eunice L Kwak
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.
Investigational new drugs 2012;30(4):1614-20.
2012: Anthony W Tolcher; Ka Wang; Zhi-Xin Xu; John F Boylan; Arvind Dasari; Mark DeMario; Jonathan Deutsch; Gerald S Falchook; Darlene G Gibbon; Astrid Koehler; Razelle Kurzrock; Eunice L Kwak; Wells A Messersmith; Steven A Middleton; Stanislaw M Mikulski; Kyriakos P Papadopoulos; Amita Patnaik; Geoffrey I Shapiro; James Song; Jennifer J Wheler
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(19):2348-53.
2012: Nils D Arvold; Lawrence S Blaszkowsky; Jeffrey W Clark; Vikram Deshpande; Carlos Fernandez-Del Castillo; Cristina R Ferrone; Eunice L Kwak; Andrzej Niemierko; David P Ryan; Raymond C Wadlow; Andrew L Warshaw; Christopher G Willett; Andrew X Zhu; Jill N Allen; Theodore S Hong
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
International journal of radiation oncology, biology, physics 2012;83(3):e337-43.
2012: Nils D Arvold; Lawrence S Blaszkowsky; Jeffrey W Clark; Carlos Fernandez-Del Castillo; Eunice L Kwak; Andrzej Niemierko; David P Ryan; Raymond C Wadlow; Jennifer Y Wo; Andrew X Zhu; Jill N Allen; Theodore S Hong
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.
Cancer 2012;118(12):3026-35.
2012: Kristin Bergethon; David P Carbone; Haiquan Chen; Jeffrey W Clark; Jeffrey A Engelman; Rong Fang; Adriana Gonzalez; Hongbin Ji; Ryohei Katayama; Eunice L Kwak; Christine M Lovly; Eugene J Mark; Pierre P Massion; Nerina T McDonald; Mari Mino-Kenudson; William Pao; Alice T Shaw; Christina Siwak-Tapp; Keith D Wilner; Sai-Hong Ignatius Ou; Julie M Batten; A John Iafrate
ROS1 rearrangements define a unique molecular class of lung cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(8):863-70.
2012: Andrew S Chi; Jeffrey W Clark; Tracy T Batchelor; Eunice L Kwak; David N Louis; Daphne L Wang; Keith D Wilner; A John Iafrate
Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(3):e30-3.
2012: Raymond C Wadlow; Brian M Wolpin; Andrew X Zhu; Thomas A Abrams; Lawrence S Blaszkowsky; Charles S Fuchs; Aram F Hezel; Matthew H Kulke; Eunice L Kwak; Jeffrey A Meyerhardt; David P Ryan; Jackie Szymonifka; Jeffrey W Clark
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
The oncologist 2012;17(1):14.
2012: Darrell R Borger; Jeffrey W Clark; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Kenneth C Fan; Valeria R Fantin; Aram F Hezel; Eunice L Kwak; Hannah M Liebman; Hector U Lopez; David P Ryan; David P Schenkein; Kimberly S Straley; Kenneth K Tanabe; Andrew X Zhu; Marek Ancukiewicz; A John Iafrate
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
The oncologist 2012;17(1):72-9.
2011: Andrew X Zhu; Deborah Schrag; Hui Zheng; Thomas A Abrams; Lawrence S Blaszkowsky; Darrell R Borger; Jeffrey W Clark; Charles S Fuchs; A John Iafrate; Kathryn R Jors; Eunice L Kwak; Jeffrey A Meyerhardt; Rebecca Miksad; Alona Muzikansky; David P Ryan
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Cancer 2011;117(22):5094-102.
2011: Alice T Shaw; Benjamin J Solomon; Yiyun Tang; Marileila Varella-Garcia; Keith D Wilner; Beow Y Yeap; Yung-Jue Bang; Mohit Butaney; Jeffrey W Clark; Daniel B Costa; Robert C Doebele; Jeffrey A Engelman; Justin Gainor; A John Iafrate; Kimary Kulig; Eunice L Kwak; ROBERT G MAKI; Sai-Hong I Ou; Gregory J Riely; Ravi Salgia; Paulina Selaru; Geoffrey I Shapiro; D Ross Camidge
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
The lancet oncology 2011;12(11):1004-12.
2011: Sai-Hong Ignatius Ou; Ravi Salgia; Christina Siwak-Tapp; Benjamin J Solomon; Weiwei Tan; Keith D Wilner; Yung-Jue Bang; Kristin Bergethon; D Ross Camidge; James Christensen; Jeffrey W Clark; Joni Dy; Dong-Wan Kim; Eunice L Kwak; ROBERT G MAKI; A John Iafrate
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(5):942-6.
2011: Jennifer R Diamond; Bruno R Bastos; Ryan J Hansen; Daniel L Gustafson; S Gail Eckhardt; Eunice L Kwak; Shuchi S Pandya; Graham C Fletcher; Todd M Pitts; Gillian N Kulikowski; Mark Morrow; Jamie Arnott; Mark R Bray; Carolyn Sidor; Wells A Messersmith; Geoffrey I Shapiro
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):849-60.
2011: Theodore S Hong; David P Ryan; Lawrence S Blaszkowsky; Harvey J Mamon; Eunice L Kwak; Mari Mino-Kenudson; Judith Adams; Beow Yeap; Barbara Winrich; Thomas F DeLaney; Carlos Fernandez-Del Castillo
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head.
International journal of radiation oncology, biology, physics 2011;79(1):151-7.
2010: Sai-Hong Ignatius Ou; Lyudmila Bazhenova; D Ross Camidge; Benjamin J Solomon; June Herman; Tatiana Kain; Yung-Jue Bang; Eunice L Kwak; Alice T Shaw; Ravi Salgia; ROBERT G MAKI; Jeffrey W Clark; Keith D Wilner; A John Iafrate
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12):2044-6.
2010: James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil H Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Janne; ROBERT G MAKI; George D Demetri; Geoffrey I Shapiro
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
The New England journal of medicine 2010;363(18):1727-33.
2010: Dora Dias-Santagata; Sara Akhavanfard; Serena S David; Kathy Vernovsky; Georgiana Kuhlmann; Susan L Boisvert; Hannah Stubbs; Ultan McDermott; Jeffrey Settleman; Eunice L Kwak; Jeffrey W Clark; Steven J Isakoff; Lecia V Sequist; Jeffrey A Engelman; Thomas J Lynch; Daniel A Haber; David N Louis; Leif W Ellisen; Darrell R Borger; A John Iafrate
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.
EMBO molecular medicine 2010;2(5):146-58.
2010: Andrew X Zhu; Jeffrey A Meyerhardt; Lawrence S Blaszkowsky; Avinash R Kambadakone; Alona Muzikansky; Hui Zheng; Jeffrey W Clark; Thomas A Abrams; Jennifer A Chan; Peter C Enzinger; Pankaj Bhargava; Eunice L Kwak; Jill N Allen; Sanjay R Jain; Keith Stuart; Kerry Horgan; Susan Sheehan; Charles S Fuchs; David P Ryan; Dushyant V Sahani
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
The lancet oncology 2010;11(1):48-54.
2009: Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; C. Rebecca Suk Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4247-53.
2009: Andrew X Zhu; Dushyant V Sahani; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A Catalano; Vivek Sindhwani; Lawrence S Blaszkowsky; Sam S Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey A Meyerhardt; Jeffrey W Clark; Eunice L Kwak; Aram F Hezel; Rebecca Miksad; Thomas A Abrams; Peter C Enzinger; Charlie S Fuchs; David P Ryan; Rakesh K Jain
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):3027-35.
2009: Eunice L Kwak; Theodore S Hong; David L Berger; David G Forcione; Raul N Uppot; Gregory Y Lauwers
Case records of the Massachusetts General Hospital. Case 19-2009. A 63-year-old woman with carcinoma of the gastroesophageal junction.
The New England journal of medicine 2009;360(25):2656-64.
2008: Robert A Figlin; Elizabeth Brown; Andrew J Armstrong; Wallace Akerley; Al B Benson; Harold J Burstein; David S Ettinger; Phillip G Febbo; Matthew G Fury; Gary R Hudes; Merrill S Kies; Eunice L Kwak; Robert J Morgan; Joanne Mortimer; Karen Reckamp; Alan P Venook; Frank Worden; Yun Yen
NCCN Task Force Report: mTOR inhibition in solid tumors.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 5():S1-20; quiz S21-2.
2008: Kofi Asomaning; Amy E Reid; Wei Zhou; C. Rebecca Suk Heist; Rihong Zhai; Li Su; Eunice L Kwak; Lawrence Blaszkowsky; Andrew X Zhu; David P Ryan; David C Christiani; Geoffrey Liu
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):4010-5.
2007: Sunitha Nagrath; Lecia V Sequist; Shyamala Maheswaran; Daphne W Bell; daniel irimia; Lindsey Ulkus; Matthew R Smith; Eunice L Kwak; Subba Digumarthy; Alona Muzikansky; Paula Ryan; Ulysses J Balis; Ronald G Tompkins; Daniel A Haber; Mehmet Toner
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Nature 2007;450(7173):1235-9.
2007: Matthew H Kulke; Lawrence S Blaszkowsky; David P Ryan; jeffrey clark; Jeffrey A Meyerhardt; Andrew X Zhu; Peter C Enzinger; Eunice L Kwak; Alona Muzikansky; Colleen Lawrence; Charlie S Fuchs
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4787-92.
2007: Eunice L Kwak; jeffrey clark; Bruce A Chabner
Targeted agents: the rules of combination.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5232-7.
2007: Eunice L Kwak; Daniel C Chung
Hereditary colorectal cancer syndromes: an overview.
Clinical colorectal cancer 2007;6(5):340-4.
2006: Eunice L Kwak; Janusz Jankowski; Sarah P Thayer; Gregory Y Lauwers; Brian W Brannigan; Patricia Neal; Ross A Okimoto; Sara M Haserlat; David R Driscoll; David Ferry; Beth Muir; Jeffrey Settleman; Charlie S Fuchs; Matthew H Kulke; David P Ryan; jeffrey clark; Dennis C Sgroi; Daniel A Haber; Daphne W Bell
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4283-7.
2006: Gromoslaw A Smolen; Beth Muir; Gayatry Mohapatra; Anne Barmettler; Woo J Kim; Miguel N Rivera; Sara M Haserlat; Ross A Okimoto; Eunice L Kwak; Sonika Dahiya; Judy E Garber; Daphne W Bell; Dennis C Sgroi; Lynda Chin; Chu-Xia Deng; Daniel A Haber
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Cancer research 2006;66(7):3452-5.
2006: Eunice L Kwak; Sang Kim; Jianmin Zhang; Robert Cardiff; Emmett V Schmidt; Daniel A Haber
Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.
Cancer research 2006;66(4):1923-8.
2005: Eunice L Kwak; Kenneth H Moberg; Doke C R Wahrer; Jennifer E Quinn; Paula M Gilmore; Colin A Graham; Iswar K Hariharan; D Paul Harkin; Daniel A Haber; Daphne W Bell
Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.
Gynecologic oncology 2005;98(1):124-8.
2005: Eunice L Kwak; Raffaella Sordella; Daphne W Bell; Nadia Godin-Heymann; Ross A Okimoto; Brian W Brannigan; Patricia Neal; David R Driscoll; Panos Fidias; Thomas J Lynch; Sridhar K Rabindran; John P McGinnis; Allan Wissner; Sreenath V Sharma; Kurt J Isselbacher; Jeffrey Settleman; Daniel A Haber
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(21):7665-70.
2005: Daniel A Haber; Daphne W Bell; Raffaella Sordella; Eunice L Kwak; Nadia Godin-Heymann; Sreenath V Sharma; Thomas J Lynch; Jeffrey Settleman
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
Cold Spring Harbor symposia on quantitative biology 2005;70():419-26.